Overview
- CMS selected medicines that together accounted for about $27 billion in recent Medicare Part B and Part D spending.
- The list includes Trulicity for diabetes, Biktarvy for HIV, and Botox for covered medical uses such as chronic migraine.
- This round marks the program’s first inclusion of clinician-administered Part B drugs, alongside Part D prescriptions.
- Companies that decline to negotiate would likely pull their products from Medicare, and no manufacturers opted out in prior rounds.
- Negotiated prices will take effect in 2028, and CMS also plans to renegotiate the Type 2 diabetes drug Tradjenta.